Today: 14 May 2026

Lockheed pitches made-in-India C-130J Super Hercules line as IAF weighs 80-plane transport buy

Lockheed pitches made-in-India C-130J Super Hercules line as IAF weighs 80-plane transport buy

Lockheed Martin has offered to set up a C-130J Super Hercules final-assembly line in India as it competes for a contract to supply up to 80 military transport aircraft. India is the only location outside the U.S. under consideration for C-130J co-production, a Lockheed executive said. Rival bids include Embraer and Airbus. Some Indian media report the air force has dropped plans for more C-130Js and is focusing on a new medium transport aircraft program.
30 December 2025
·
Amphenol stock slips in year-end tech pullback; Fed minutes and housing data loom

Amphenol stock slips in year-end tech pullback; Fed minutes and housing data loom

Amphenol shares closed down 0.4% at $136.90 Monday as tech stocks dragged U.S. markets lower in thin year-end trading. The stock traded between $135.83 and $137.59 on volume of 4.3 million shares. Amphenol will report fourth-quarter results on Jan. 28. Investors are watching upcoming U.S. economic data and Federal Reserve minutes for further direction.
30 December 2025
·······
AMAT stock ends higher in thin year-end trade as tech slips — what investors are watching next

AMAT stock ends higher in thin year-end trade as tech slips — what investors are watching next

Applied Materials shares closed up 0.44% at $263.05 Monday, near their 52-week high, as broader markets slipped and trading volume remained light. The stock outperformed peers Lam Research and KLA, which both declined. Investors remain focused on U.S. export controls affecting China sales and upcoming earnings, expected Feb. 12, 2026. After-hours, Applied Materials dipped 0.13%.
30 December 2025
·
Society Pass (SOPA) stock jumps 61% after TikTok Shop live-commerce launch in Thailand

Society Pass (SOPA) stock jumps 61% after TikTok Shop live-commerce launch in Thailand

Society Pass shares soared 61% to $2.93 on volume of 153 million after launching a TikTok Shop live-commerce platform in Thailand. The stock traded between $2.21 and $3.46, far above typical activity. Executives set a $10 million revenue target for the new business line in 2026. Traders are watching for early traction and updates on earnings.
30 December 2025
···
CrowdStrike stock slips as CEO George Kurtz gets new performance award tied to $20B ARR goal

CrowdStrike stock slips as CEO George Kurtz gets new performance award tied to $20B ARR goal

CrowdStrike disclosed a new performance-based equity award for CEO George Kurtz, potentially delivering up to 600,000 shares if the stock outperforms most of the S&P 500 over three years, according to an SEC filing. Shares closed down 1.1% at $475.91 on Monday. Chief Accounting Officer Anurag Saha sold 836 shares at $476.83 on Dec. 24. Investors await Fed minutes as holiday trading thins.
30 December 2025
··
Target stock drops after activist buzz fades; Fed minutes set the next test for TGT

Target stock drops after activist buzz fades; Fed minutes set the next test for TGT

Target fell 1.4% to $98.10 Monday, erasing part of last week’s activist-driven gains as trading volume stayed light. The move followed news that Toms Capital took a significant but undisclosed stake. Investors await Tuesday’s Fed minutes and any updates from the activist investor. Target has no investor events scheduled before its next earnings report, expected in early March.
30 December 2025
·····
Synopsys stock closes higher as traders eye Dec. 30 lawsuit deadline and Fed minutes

Synopsys stock closes higher as traders eye Dec. 30 lawsuit deadline and Fed minutes

Synopsys shares rose 0.4% to $478.97 Monday, outperforming the Nasdaq as broader markets slipped in thin year-end trading. Investor-law firms reminded shareholders of a Dec. 30 deadline in a securities class-action case tied to alleged misstatements in the company’s Design IP business. About 1.33 million Synopsys shares traded, with the stock moving between $471.28 and $484.33.
30 December 2025
··
MercadoLibre (MELI) stock price today: Shares edge higher into Fed minutes as year-end trading thins

MercadoLibre (MELI) stock price today: Shares edge higher into Fed minutes as year-end trading thins

MercadoLibre shares closed up 0.4% at $2,014.97 on Monday, outperforming declines in major U.S. indexes. The stock traded between $1,986 and $2,037 during the session. Traders are awaiting Federal Reserve meeting minutes Tuesday and a holiday-shifted jobless claims report Wednesday. MercadoLibre’s next scheduled earnings release is set for late February.
30 December 2025
·
KLA stock drops after tech pullback hits chip equipment names; Fed minutes next

KLA stock drops after tech pullback hits chip equipment names; Fed minutes next

KLA Corp shares fell 1.5% to $1,260.39 Monday, ending a six-session winning streak as tech stocks retreated in thin year-end trading. The Philadelphia Semiconductor Index dropped 0.41%. KLA’s volume was lighter than usual, with 625,000 shares traded versus a 993,000 average. Investors await Fed minutes and jobless claims later this week.
30 December 2025
······
1 … 970 971 972 973 974 … 1,935

Stock Market Today

  • Ecovyst Earnings Show Potential Despite Weak Recent Results
    May 14, 2026, 4:15 PM EDT. Ecovyst Inc. (NYSE:ECVT) reported weak recent earnings, dampening immediate market response. However, a $16 million unusual expense, one-off in nature, obscures the company's underlying profit potential. Analysts expect improved profitability if these one-time costs do not recur. Though earnings per share (EPS) declined over the past year, the company's earnings potential remains promising. Investors should note Ecovyst faces three warning signs, highlighting risks to consider before investing. Overall, the outlook for Ecovyst's profits appears cautiously optimistic, with future quarters likely to reflect better results absent unusual charges.

Latest articles

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

14 May 2026
REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

14 May 2026
Digi Power X shares fell 14% to $7.28 in heavy trading Thursday ahead of its first-quarter results and operations update due May 15. Investors are focused on its $1.1 billion, 10-year AI data-center deal with Cerebras and a $19.6 million SubQ AI GPU rental contract launching Friday. The company also expanded its at-the-market share-sale program to $175 million.
Go toTop